Q-omics provides the consensus-scored RETREG1 profile across patient tissues and cancer cell-line models. RETREG1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RETREG1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RETREG1 RNA expression shows 18,829 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RETREG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RETREG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RETREG1 survival associations across molecular data types. RETREG1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RETREG1 RNA expression–survival associations across cancer types. High RETREG1 expression shows unfavorable associations in UVM, but favorable associations in KIRC, ACC, KIRP, MESO and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RETREG1 RNA expression.
This table summarizes RETREG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RETREG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RETREG1 shows lower tumor expression in COAD, LUAD, LIHC, LUSC and READ and higher tumor expression in KIRP. The COAD box plot shows higher RETREG1 RNA expression in normal versus tumor tissue (log2 FC = −1.532, t-test p < 0.001).
This table shows molecular features associated with RETREG1 in patient tissues and cancer cell lines. In patient samples, RETREG1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RETREG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
